1. Core Mission The goal of the Developmental Core is to stimulate new investigator-initiated research breakthroughs in HIV/AIDS through the support of CFAR faculty utilizing three major mechanisms;direct financial support to allow recruitment of talented faculty in targeted areas who complement and enhance the CFAR HIV research agenda (Faculty Development);research support through the peer-reviewed Small Grants and Emerging Opportunities Awards;and the fostering of young investigators through a structured training and mentoring program, the Mentored Clinical Research Scientist Program (MCRSP). The MCRSP was initiated in the current cycle of funding, and it will be continued and expanded in the next funding cycle to reach a larger pool of junior trainees engaged in HIV-related research. Ultimately a more formal program in mentoring across the Cores will be developed. Much has been accomplished over the past four years due to the impact of the CFAR Developmental Core in support of HIV/AIDS research. The effectiveness of the Developmental Core is due, in part, to the fact that nearly all HIV-related research at Duke is coordinated and led by the Duke CFAR faculty, resulting in a cohesive research community that is accustomed to working together across academic departmental boundaries to form multidisciplinary and interdepartmental teams. Illustrative of this collaborative environment are the numerous publications co-authored by members of different departments (See Table I and References 1-28 for a listing of key CFAR personnel who are either first or senior authors, and their collaborators, on publications since 2004). The Developmental Core's role in this process has been in the implementation and coordination of the supportive mechanisms defined above. Final decisions concerning the establishment of priorities and allocation of resources resides with the CFAR Executive Committee and CFAR leadership, which allows flexibility in resource allocation to take advantage of opportunities and to correct weaknesses if any. Institutional support in the form of matching funds from the Dean of the School of Medicine has been made available to further enhance CFAR Developmental Core activities, providing additional leveraged resources to expand Faculty Development, and Small Grants and Emerging Opportunities Awards. Thus, as the Duke CFAR moves forward in its second funding cycle, there is a firm foundation of coordination, cooperation and communication among CFAR members, members of the Duke research community at-large who are working on HIV-related projects, and the leadership ofthe School of Medicine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI064518-08
Application #
8379350
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2012
Total Cost
$421,401
Indirect Cost
$82,045
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Ramadhani, Habib O; Muiruri, Charles; Maro, Venance P et al. (2017) Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance. AIDS Behav :
Han, Qifeng; Williams, Wilton B; Saunders, Kevin O et al. (2017) HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. J Virol 91:
Margolis, David M; Koup, Richard A; Ferrari, Guido (2017) HIV antibodies for treatment of HIV infection. Immunol Rev 275:313-323
Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221
Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan et al. (2017) Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice J Virol 91:
Price, Alexander M; Dai, Joanne; Bazot, Quentin et al. (2017) Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. Elife 6:
Martinez, David R; Vandergrift, Nathan; Douglas, Ayooluwa O et al. (2017) Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. J Virol 91:
Marks, Florian; von Kalckreuth, Vera; Aaby, Peter et al. (2017) Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 5:e310-e323
Towe, Sheri L; Patel, Puja; Meade, Christina S (2017) The Acceptability and Potential Utility of Cognitive Training to Improve Working Memory in Persons Living With HIV: A Preliminary Randomized Trial. J Assoc Nurses AIDS Care 28:633-643
Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2017) The Nasopharyngeal Microbiota of Children With Respiratory Infections in Botswana. Pediatr Infect Dis J 36:e211-e218

Showing the most recent 10 out of 468 publications